CA2544035C - Utilization of vinpocetine to avoid complications in particular those associated to hearing which occur with epilepsy, and treatment thereof - Google Patents
Utilization of vinpocetine to avoid complications in particular those associated to hearing which occur with epilepsy, and treatment thereof Download PDFInfo
- Publication number
- CA2544035C CA2544035C CA2544035A CA2544035A CA2544035C CA 2544035 C CA2544035 C CA 2544035C CA 2544035 A CA2544035 A CA 2544035A CA 2544035 A CA2544035 A CA 2544035A CA 2544035 C CA2544035 C CA 2544035C
- Authority
- CA
- Canada
- Prior art keywords
- vinpocetine
- epilepsy
- abr
- ptz
- induced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 title claims abstract description 78
- 229960000744 vinpocetine Drugs 0.000 title claims abstract description 78
- 206010015037 epilepsy Diseases 0.000 title claims abstract description 34
- 238000011282 treatment Methods 0.000 title claims abstract description 16
- 230000001709 ictal effect Effects 0.000 claims abstract description 16
- 206010011878 Deafness Diseases 0.000 claims abstract description 15
- 230000001054 cortical effect Effects 0.000 claims abstract description 15
- 230000010370 hearing loss Effects 0.000 claims abstract description 15
- 231100000888 hearing loss Toxicity 0.000 claims abstract description 15
- 208000016354 hearing loss disease Diseases 0.000 claims abstract description 15
- 230000001037 epileptic effect Effects 0.000 claims abstract description 8
- 230000004075 alteration Effects 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 13
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 230000000985 convulsing effect Effects 0.000 abstract description 10
- 230000005856 abnormality Effects 0.000 abstract description 6
- 230000002411 adverse Effects 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 2
- 230000009291 secondary effect Effects 0.000 abstract description 2
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 55
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 45
- 229960005152 pentetrazol Drugs 0.000 description 45
- 238000002347 injection Methods 0.000 description 29
- 239000007924 injection Substances 0.000 description 29
- 230000007423 decrease Effects 0.000 description 10
- 206010010904 Convulsion Diseases 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 241000700198 Cavia Species 0.000 description 5
- 210000000133 brain stem Anatomy 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 230000019771 cognition Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000003078 Generalized Epilepsy Diseases 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 239000003179 convulsant agent Substances 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- 210000003984 auditory pathway Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000008579 epileptogenesis Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 1
- 229960005318 vigabatrin Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/MX2003/000089 WO2005039482A2 (es) | 2003-10-28 | 2003-10-28 | Uso de la vinpocetina para prevenir las complicaciones, particularmente las relacionadas con la audición, que acompañan a la epilepsia y su tratamiento |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2544035A1 CA2544035A1 (en) | 2005-05-06 |
| CA2544035C true CA2544035C (en) | 2012-01-10 |
Family
ID=34511293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2544035A Expired - Lifetime CA2544035C (en) | 2003-10-28 | 2003-10-28 | Utilization of vinpocetine to avoid complications in particular those associated to hearing which occur with epilepsy, and treatment thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070135470A1 (zh) |
| EP (1) | EP1679059A4 (zh) |
| JP (1) | JP2007521241A (zh) |
| CN (1) | CN100500146C (zh) |
| AU (1) | AU2003274807A1 (zh) |
| BR (1) | BR0318588A (zh) |
| CA (1) | CA2544035C (zh) |
| HK (1) | HK1100348A1 (zh) |
| MX (1) | MXPA06004690A (zh) |
| NZ (1) | NZ547508A (zh) |
| WO (1) | WO2005039482A2 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2678544C (en) * | 2007-02-15 | 2016-06-28 | The Board Of Trustees Of The University Of Illinois | Non-invasive, bedside intra-cranial pressure monitoring system utilizing early on-set auditory evoked responses |
| CN107614498B (zh) * | 2015-02-04 | 2020-06-05 | 哈药集团制药总厂 | 二氮杂-苯并荧蒽类化合物 |
| MX2018002786A (es) * | 2015-09-03 | 2018-12-17 | Neolpharma Inc | Composicion farmaceutica de vinpocetina. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU201674B (en) * | 1987-08-26 | 1990-12-28 | Richter Gedeon Vegyeszet | Process for producing pharmaceutical composition suitable for curing autoimmune-type leukoencephalomyelitic diseases e.g. sclerosis multiplex |
| EP0813411B1 (en) * | 1995-02-15 | 2002-01-23 | Takeda Chemical Industries, Ltd. | Use of vinpocetine derivatives for inhibiting production or secretion of amyloid beta protein |
-
2003
- 2003-10-28 JP JP2005509879A patent/JP2007521241A/ja active Pending
- 2003-10-28 CN CNB2003801109285A patent/CN100500146C/zh not_active Expired - Lifetime
- 2003-10-28 CA CA2544035A patent/CA2544035C/en not_active Expired - Lifetime
- 2003-10-28 EP EP03759058A patent/EP1679059A4/en not_active Ceased
- 2003-10-28 WO PCT/MX2003/000089 patent/WO2005039482A2/es active Application Filing
- 2003-10-28 AU AU2003274807A patent/AU2003274807A1/en not_active Abandoned
- 2003-10-28 BR BRPI0318588-5A patent/BR0318588A/pt not_active Application Discontinuation
- 2003-10-28 US US10/577,620 patent/US20070135470A1/en not_active Abandoned
- 2003-10-28 NZ NZ547508A patent/NZ547508A/en not_active IP Right Cessation
-
2006
- 2006-04-27 MX MXPA06004690A patent/MXPA06004690A/es active IP Right Grant
-
2007
- 2007-08-03 HK HK07108463.4A patent/HK1100348A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003274807A8 (en) | 2005-05-11 |
| WO2005039482A2 (es) | 2005-05-06 |
| US20070135470A1 (en) | 2007-06-14 |
| EP1679059A2 (en) | 2006-07-12 |
| NZ547508A (en) | 2010-04-30 |
| EP1679059A4 (en) | 2009-11-04 |
| CN100500146C (zh) | 2009-06-17 |
| AU2003274807A1 (en) | 2005-05-11 |
| HK1100348A1 (en) | 2007-09-21 |
| BR0318588A (pt) | 2006-10-17 |
| WO2005039482A3 (es) | 2005-09-01 |
| CN1909782A (zh) | 2007-02-07 |
| JP2007521241A (ja) | 2007-08-02 |
| MXPA06004690A (es) | 2006-07-05 |
| CA2544035A1 (en) | 2005-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fan et al. | Research progress of vagus nerve stimulation in the treatment of epilepsy | |
| Henry et al. | Underlying mechanisms of tinnitus: review and clinical implications | |
| Chatrian et al. | The significance of periodic lateralized epileptiform discharges in EEG: an electrographic, clinical and pathological study | |
| Moll et al. | Deficient intracortical inhibition in drug-naive children with attention-deficit hyperactivity disorder is enhanced by methylphenidate | |
| Soriano et al. | The effect of propofol on intraoperative electrocorticography and cortical stimulation during awake craniotomies in children | |
| McVicar et al. | Landau–Kleffner syndrome, electrical status epilepticus in slow wave sleep, and language regression in children | |
| Ishikawa et al. | The effect of memantine on sleep architecture and psychiatric symptoms in patients with Alzheimer’s disease | |
| Coelho et al. | Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: an open-label pilot study | |
| Mathew et al. | Lateral asymmetries in auditory acuity distinguish hallucinating from nonhallucinating schizophrenic patients | |
| Serafetinides et al. | EEG patterns induced by intracarotid injection of sodium amytal | |
| Davison | EEG activation after intravenous amitriptyline | |
| Polo et al. | Mismatch negativity and auditory sensory memory in chronic alcoholics | |
| CA2544035C (en) | Utilization of vinpocetine to avoid complications in particular those associated to hearing which occur with epilepsy, and treatment thereof | |
| Sitges et al. | Vinpocetine prevents 4-aminopyridine-induced changes in the EEG, the auditory brainstem responses and hearing | |
| Turkdogan et al. | Visual and auditory event related potentials in epileptic children: a comparison with normal and abnormal MRI findings | |
| RU2376990C2 (ru) | Применение винпоцетина для предупреждения осложнений, в частности осложнений, связанных со слухом, которые сопутствуют эпилепсии и ее лечению | |
| Chayasirisobhon et al. | Recording of brainstem evoked potentials and their association with gentamicin in neonates | |
| Nekrassov et al. | Comparison of acute, chronic and post-treatment effects of carbamazepine and vinpocetine on hearing loss and seizures induced by 4-aminopyridine | |
| Lang et al. | Neurophysiological findings in the northern epilepsy syndrome | |
| Male et al. | Methohexitone-induced convulsions in epileptics | |
| Foreman | Generalized periodic discharges with triphasic morphology | |
| Pierantozzi et al. | Curariform peripheral block of muscular tone selectively increases precentral N30 somatosensory evoked potentials component. A pharmacological study carried out on healthy subjects and parkinsonian syndromes | |
| KR20060125756A (ko) | 간질과 함께 발생하는 합병증, 특히 청력 관련 합병증의예방 및 치료를 위한 빈포세틴의 용도 | |
| Hanaya et al. | Total intravenous anesthesia affecting spike sources of magnetoencephalography in pediatric epilepsy patients: Focal seizures vs. non-focal seizures | |
| NEELAM et al. | EVENT RELATED EVOKED POTENTIALS IN DEMENTIA ROLE OF VITAMIN E |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20231030 |